KIT and chronic myelogenous leukemia, BCR-ABL1 positive: A previous study has shown that Dasatinib not only inhibits the BCR-ABL kinase of chronic myeloid leukemia, but also inhibits KIT kinase, including KIT mutation encoded KIT kinase.